Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant

Iben Kümler,1 Ann S Knoop,2 Christina A R Jessing,1 Bent Ejlertsen,2 Dorte L Nielsen1

ABSTRACT

Background: Endocrine therapy constitutes a central modality in the treatment of oestrogen receptor (ER)-positive advanced breast cancer.

Purpose: To evaluate the evidence for endocrine treatment in postmenopausal patients with advanced breast cancer focusing on the aromatase inhibitors, letrozole, anastrozole, exemestane and fulvestrant.

Methods: A review was carried out using PubMed. Randomised phase II and III trials reporting on ≥100 patients were included.

Results: 35 trials met the inclusion criteria. If not used in the adjuvant setting, a non-steroid aromatase inhibitor was the optimal first-line option. In general, the efficacy of the different aromatase inhibitors and fulvestrant was similar in tamoxifen-refractory patients. A randomised phase II trial of palbociclib plus letrozole versus letrozole alone showed significantly increased progression-free survival (PFS) when compared with endocrine therapy alone in the first-line setting (20.2 vs 10.2 months). Furthermore, the addition of everolimus to exemestane in the Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2) study resulted in an extension of median PFS by 4.5 months after recurrence/progression on a non-steroid aromatase inhibitor. However, overall survival was not significantly increased.

Conclusion: Conventional treatment with an aromatase inhibitor or fulvestrant may be an adequate treatment option for most patients with hormone receptor-positive advanced breast cancer. Mammalian target of rapamycin (mTOR) inhibition and cyclin-dependent kinase 4/6 (CDK4/6) inhibition might represent substantial advances for selected patients in some specific settings. However, there is an urgent need for prospective biomarker-driven trials to identify patients for whom these treatments are cost-effective.

INTRODUCTION

Breast cancer is strongly related to age. The highest incidence rates are found in older, postmenopausal women. Approximately 70–80% of breast cancers are oestrogen and/or progesterone receptor (ER/PGR) positive and, thus, potentially sensitive to endocrine therapy.

After menopause, about 90% of the total body oestrogens are synthesised by aromatisation of androstenedione into oestrone, and the production may be blocked by aromatase inhibitors (AIs). The first AI with documented antitumour efficacy was aminoglutethimide. Following this, second-generation and third-generation AIs have been developed. The third-generation inhibitors including letrozole, anastrozole and exemestane have increased potency associated with better clinical efficacy compared with aminoglutethimide or the second-generation inhibitor fadrozole.2 Pharmacologically, AIs may be subdivided into two classes: non-steroidal AI (NSAI) represented by letrozole and anastrozole, and steroidal AI (SAI) represented only by exemestane. Both groups of AIs block aromatase activity: SAIs inhibit the aromatase in a reversible manner by binding to the haem moiety of the enzyme, thus preventing androgens from binding to the catalytic site. SAIs bind covalently to the substrate binding site of the aromatase, irreversibly inactivating the enzyme.2 Apart from AIs, endocrine treatment consists of the selective ER modulator (SERM) tamoxifen and the pure anti-oestrogen fulvestrant. Tamoxifen has mixed agonistic and antagonistic activity, depending on the target tissue. In contrast, fulvestrant is a complete ER antagonist which in addition introduces a conformational change leading to monomers degrading ER,3–5 theoretically overcoming resistance driven by the agonist properties of tamoxifen.

The purpose of this review was to evaluate outcome in clinical trials performed in postmenopausal patients with advanced breast cancer treated with various endocrine...
regimens, including letrozole, anastrozole, exemestane and fulvestrant.

**METHODS**

No review protocol exists. However, before initiating the review, we decided on a search strategy in which PubMed was searched for human studies using the ‘clinical trial’ filter and the following search terms: AI, endocrine therapy and advanced/metastatic breast cancer. In addition, we searched for the specific drugs. Papers from 1980 and onwards were included. In total, 535 articles were identified. Subsequently, we applied the following exclusion criteria: phase I and non-randomised phase II trials, dose-finding studies, studies on first-generation or second-generation AIs, trials including <100 patients, studies reporting on various antihormonal treatments in which it was not possible to distinguish between the different outcomes, preclinical studies and reviews. Articles on exploratory subgroup analyses and studies evaluating the compounds in premenopausal women or including premenopausal and postmenopausal patients were also excluded. Fully published, randomised phase II or III trials in English were included. Full articles were obtained and references were checked for additional material when appropriate. The reference list was updated in October 2015.

Two authors (IK and DLN) independently surveyed the literature. In case of unclarity, a verdict was reached by consensus.

**RESULTS**

A total of 35 trials were included in the present review.

**Studies comparing AIs or fulvestrant with an antioestrogen, megestrol acetate or a first-generation AI**

In total, 11 trials were identified, including 1 phase II–III and 10 phase III trials. Results are presented in table 1.

**First-line therapy**

**NSAIs versus tamoxifen**

Three phase III studies compared anastrozole with tamoxifen as first-line therapy. The TAMOXifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability (TARGET) trial including 668 women (43% known hormone receptor (HR) positive) found the two treatments to be equivalent regarding response rate (RR) and time to progression (TTP).8 The North American Multicenter Randomized trial (NAT) trial included 353 patients among which almost 90% were HR positive. The RR was similar in the two arms; however, anastrozole had a significant advantage over tamoxifen in terms of a nearly doubling of TTP. The two studies had a similar design and were prospectively planned for a combined analysis. Among all included patients, TTP was similar in the two groups. However, a subgroup analysis among HR-positive patients (~60%) revealed a TTP of 10.7 months in the anastrozole group compared with 6.4 months in the tamoxifen group (p=0.022). Median time to death was 40.8 and 41.3 months, respectively.8 9 Crossover was not preplanned in these studies.

A third trial in ER-positive, hormonal therapy-naïve patients showed significant advantage of anastrozole regarding clinical benefit rate (CBR), TTP and median time to death.10

The P025 trial of letrozole versus tamoxifen in 907 patients showed superiority of letrozole, regarding RR and TTP. The findings were irrespective of prior adjuvant antioestrogen treatment.11 12 The overall survival (OS), however, was not statistically different.13 Approximately half of the patients in each arm crossed over to the other agent on progression. Thus, OS results might have been confounded. Indeed, a planned statistical analysis 2 years after randomisation showed a 62% vs 57% survival in the letrozole and tamoxifen group, respectively (p=0.0246).14

**SAI versus tamoxifen**

A phase II/III trial comparing exemestane with tamoxifen showed an increased RR after exemestane and early significant differences in progression-free survival (PFS) (Wilcoxon p=0.028). However, this early finding did not translate into a significant benefit in PFS or OS.15 16

**Fulvestrant (250 mg) versus tamoxifen**

A phase III non-inferiority trial including 587 patients compared fulvestrant (250 mg) with tamoxifen. Approximately 78% of the patients were HR positive and ~25% had received adjuvant tamoxifen prior to inclusion. Overall RR and TTP were not significantly different. In addition, a prospectively planned analysis of patients with known HR-positive status showed equal efficacy of the drugs. Estimated OS was 36.9 months in the fulvestrant group and 38.7 months in the tamoxifen group (HR 1.29; p=0.04).17 In the subgroup of patients who had received adjuvant tamoxifen, the results were similar to those of the whole population.

**First-line or second-line therapy**

**NSAIs versus megestrol acetate**

Two phase III trials compared two doses of anastrozole with megestrol acetate regarding TTP and OS on an initial analysis was found.18 19 However, a planned subsequent analysis of anastrozole 1 mg to be associated with significantly increased OS compared with megestrol acetate (26.7 vs 22.5 months; p<0.025).20

Two different doses of letrozole were compared with megestrol acetate as second-line therapy in women previously treated with antioestrogen in two phase III trials. The first study included 602 women (80–85% HR positive). RR was not significantly different among the three treatment regimens. However, patients treated with letrozole 0.5 mg had a significantly longer TTP (5.6 vs...
<table>
<thead>
<tr>
<th>Reference</th>
<th>Treatment*</th>
<th>Number of patients</th>
<th>Patient population</th>
<th>Phase</th>
<th>Prior endocrine therapy</th>
<th>Prior chemotherapy for ABC</th>
<th>RR (%) (95% CI)</th>
<th>SD (%) (95% CI)</th>
<th>TTP/PFS (median; months) (95% CI)</th>
<th>OS (median; months) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First-line therapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSAIs vs tamoxifen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bonneterre et al</td>
<td>Anastrozole</td>
<td>340</td>
<td>ER/PGR+ (UK 54/56%); (TARGET)</td>
<td>III</td>
<td>None: 89/88%; &gt;12 months adj TAM: 11/12%</td>
<td>None</td>
<td>32.9</td>
<td>23.2</td>
<td>8.2; ER/PGR+: 8.9</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>Tamoxifen</td>
<td>328</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nabholz et al</td>
<td>Anastrozole</td>
<td>171</td>
<td>ER+ (UK 11/11%)</td>
<td>III (NAT)</td>
<td>None: 82/79%; &gt;12 months adj TAM: 18/21%</td>
<td>None</td>
<td>21</td>
<td>17</td>
<td>11.1</td>
<td>5.8 (p=0.005)</td>
</tr>
<tr>
<td></td>
<td>Tamoxifen</td>
<td>182</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Milla-Santos et al</td>
<td>Anastrozole</td>
<td>121</td>
<td>ER+</td>
<td>III</td>
<td>None</td>
<td>None</td>
<td>35</td>
<td>29</td>
<td>18.0</td>
<td>17.4</td>
</tr>
<tr>
<td></td>
<td>Tamoxifen</td>
<td>117</td>
<td>40 mg</td>
<td></td>
<td></td>
<td></td>
<td>26 (p=0.172)</td>
<td>29</td>
<td>7.0 (HR 0.13; p&lt;0.01)</td>
<td>16.0 (HR 0.64; p=0.003)</td>
</tr>
<tr>
<td>Mouridsen et al</td>
<td>Letrozole</td>
<td>453</td>
<td>ER/PGR+ (UK 34/33%)</td>
<td>III</td>
<td>None: 81/82%; &gt;12 months adj TAM: 19/18%</td>
<td>≤1</td>
<td>30</td>
<td>49 (44 to 54) (CBR)</td>
<td>9.4</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>Tamoxifen</td>
<td>454</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>38 (34 to 43)</td>
<td>6.0 (p=0.0001)</td>
<td>30 (p=0.53)</td>
</tr>
<tr>
<td>SAI vs tamoxifen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paridaens et al</td>
<td>Exemestane</td>
<td>182</td>
<td>Hormone receptor+ (UK 8/5%)</td>
<td>II/III</td>
<td>None: 79/61%; &gt;6 months adj TAM: 21/21%</td>
<td>≤1</td>
<td>46</td>
<td>29.7†</td>
<td>9.9 (8.7 to 11.8)</td>
<td>p=0.821</td>
</tr>
<tr>
<td></td>
<td>Tamoxifen</td>
<td>189</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31 (OR 1.85; 1.21 to 2.31; p=0.005)</td>
<td>35.4</td>
<td>5.8 (5.3 to 8.1) (HR 0.84; p=0.121)</td>
</tr>
<tr>
<td>Fulvestrant vs tamoxifen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Howell 2004 et al</td>
<td>Fulvestrant</td>
<td>313</td>
<td>ER/PGR+ (UK 18/20%; ER−/PGR− 1/1%)</td>
<td>III</td>
<td>None: 78/75%; &gt;12 months adj TAM: 22/25%</td>
<td>None</td>
<td>31.8</td>
<td>54.3† (CBR)</td>
<td>6.8</td>
<td>36.9 (estimated)</td>
</tr>
<tr>
<td></td>
<td>Tamoxifen</td>
<td>274</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>33.9 (OR 0.87; 0.61 to 1.24; p=0.45)</td>
<td>62.0</td>
<td>8.3 (HR 1.18; p=0.088)</td>
</tr>
<tr>
<td><strong>First-line or second-line therapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSAIs vs megestrol acetate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buzdar et al</td>
<td>Anastrozole</td>
<td>128</td>
<td>ER+ or prior sensitivity to TAM (UK 13/15/13%)</td>
<td>III</td>
<td>PD on antioestrogen‡; adj antioestrogen: 47/42/39%</td>
<td>≤1</td>
<td>10</td>
<td>27</td>
<td>5.6</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>Anastrozole 1 mg</td>
<td>128</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anastrozole 10 mg</td>
<td>130</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Megestrol acetate</td>
<td>128</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>Reference</th>
<th>Number of patients</th>
<th>Treatment*</th>
<th>Patient population</th>
<th>Phase</th>
<th>Prior endocrine therapy</th>
<th>Prior chemotherapy for ABC</th>
<th>RR (%) (95% CI)</th>
<th>SD (%) (95% CI)</th>
<th>TTP/PFS (median; months) (95% CI)</th>
<th>OS (median; months) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonat et al†9</td>
<td>135</td>
<td>Anastrozole 1 mg</td>
<td>ER/PGR+ (UK 34/39/38%)</td>
<td>III</td>
<td>PD after/on TAM; adj TAM: 49/39/42%; first-line TAM: 51/61/58%</td>
<td>≤1</td>
<td>34.1</td>
<td>34.0 (CBR)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>118</td>
<td>Anastrozole 10 mg</td>
<td>ER/PGR+ (UK 34/39/38%)</td>
<td></td>
<td></td>
<td></td>
<td>33.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>125</td>
<td>Megestrol acetate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>32.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buzdar et al†1</td>
<td>202</td>
<td>Letrozole 0.5 mg</td>
<td>ER/PGR+ (UK 13/15/13%)</td>
<td>III</td>
<td>PD on antioestrogen‡; adj antioestrogen: 47/42/39%; first-line antioestrogen: 53/58/61%</td>
<td>≤2</td>
<td>21 (15.2 to 26.4)</td>
<td>12.4</td>
<td>5.6 (3.3 to 6.3)</td>
<td>33.1 (26.7 to 39.4)</td>
</tr>
<tr>
<td></td>
<td>199</td>
<td>Letrozole 2.5 mg</td>
<td>ER/PGR+ (UK 13/15/13%)</td>
<td></td>
<td></td>
<td></td>
<td>16 (11.0 to 21.2)</td>
<td>10.6</td>
<td>3.2 (3.0 to 5.3)</td>
<td>26.6 (25.0 to 33.8)</td>
</tr>
<tr>
<td></td>
<td>201</td>
<td>Megestrol acetate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>15 (10.0 to 19.9)</td>
<td>8.5</td>
<td>3.4 (3.0 to 5.6)</td>
<td>26.2 (21.7 to 29.9)</td>
</tr>
<tr>
<td>Dombernowsky et al†2</td>
<td>188</td>
<td>Letrozole 0.5 mg</td>
<td>ER/PGR+ (UK 45/43/41%)</td>
<td>III</td>
<td>PD on antioestrogen‡; adj antioestrogen: 35/33/32%</td>
<td>≤1</td>
<td>13 (p=0.004)</td>
<td>14.4</td>
<td>5.1 (p=0.02)</td>
<td>1.34 (risk ratio)</td>
</tr>
<tr>
<td></td>
<td>174</td>
<td>Letrozole 2.5 mg</td>
<td>ER/PGR+ (UK 45/43/41%)</td>
<td></td>
<td></td>
<td></td>
<td>24</td>
<td>10.9</td>
<td>5.6 (p=0.07)</td>
<td>0.82</td>
</tr>
<tr>
<td></td>
<td>189</td>
<td>Megestrol acetate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>16 (p=0.04)</td>
<td>15.3</td>
<td>5.5</td>
<td>1.12</td>
</tr>
<tr>
<td>SAI vs megestrol acetate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaufmann et al†3</td>
<td>366</td>
<td>Exemestane</td>
<td>ER/PGR+ (UK+or prior sensitivity to TAM (UK 33/32%))</td>
<td>III</td>
<td>PD on TAM‡; adj TAM: NR</td>
<td>≤1</td>
<td>15</td>
<td>37.4 (CBR)</td>
<td>4.5</td>
<td>Not reached</td>
</tr>
<tr>
<td></td>
<td>404</td>
<td>Megestrol acetate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>012.4 (NS)</td>
<td>34.6 (NS)</td>
<td>3.7 (p=0.037)</td>
<td>27.4 (p=0.039)</td>
</tr>
</tbody>
</table>

For RR, SD, duration of TTP/PFS and OS, the number of decimals reported by the authors is given.
ER/PGR+, HER2: numbers are given when possible.
*Unless stated, doses of tamoxifen, megestrol acetate, anastrozole, letrozole and exemestane were 20, 160, 1, 2.5 and 25 mg, respectively.
†Duration of SD not reported; if not marked, duration of SD reported ≥24 weeks or 6 months.
‡Defined as relapse on adjuvant antioestrogen or within 12 months of stopping treatment or progression on first-line antioestrogen therapy.
ABC, advanced breast cancer; Adj, adjuvant; AI, aromatase inhibitor; CBR, clinical benefit rate; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; NR, not reported; NS, non-significant; NSAI, non-steroid aromatase inhibitor; PD, progressive disease; PFS, progression-free survival; PGR, progesterone receptor; RR, response rate; SAI, steroid aromatase inhibitor; TAM, tamoxifen; TARGET, Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability; TTP, time to progression; OS, overall survival; UK, unknown.
3.4 months) and a decreased risk of treatment failure compared with patients treated with megestrol acetate. Letrozole 0.5 mg showed a trend (p=0.053) towards a survival benefit. The second study included 551 patients. The RR was significantly higher for letrozole 2.5 mg (24%) compared with letrozole 0.5 mg (13%) or megestrol acetate (16%). TTP for letrozole 2.5 mg was superior to letrozole 0.5 mg, but not to megestrol acetate. There was a significant dose effect on OS in favour of letrozole 2.5 mg (p=0.03) compared with letrozole 0.5 mg. The OS was similar in the letrozole 2.5 mg and megestrol acetate arms. However, letrozole was significantly better tolerated than megestrol acetate.

**SAI versus megestrol acetate**

A randomised phase II trial comparing exemestane with megestrol acetate in patients who had experienced tamoxifen failure showed significantly increased TTP and OS in favour of exemestane.

**Studies comparing the individual AIs with each other or with fulvestrant, or combinations**

A total of 12 trials were identified: one randomised phase II, nine phase III, one phase III–IV and one study with combined data from two phase III trials. Efficacy results are given in table 2.

**First-line therapy**

**Exemestane versus anastrozole**

One phase III trial compared exemestane with anastrozole in patients who had been treated with tamoxifen. RRs and TTP were identical in the two arms. Likewise, a randomised phase II trial found the clinical activity of the two drugs to be equal.

**Fulvestrant (500 mg) versus anastrozole**

The Fulvestrant First-Line Study Comparing Endocrine Treatments (FIRST) trial was a phase II trial comparing fulvestrant (500 mg) with anastrozole as first-line treatment. Approximately 25% of the patients had received adjuvant endocrine therapy (the number of patients receiving an AI was not reported). RR and CBR were comparable in the treatment arms; however, TTP was 23.4 and 13.1 months, respectively, for fulvestrant and anastrozole, indicating superiority of fulvestrant to anastrozole in this setting. It should be noted that TTP was a secondary end point.

**Combination therapy versus single agent**

The Fulvestrant and Anastrozole Combination Therapy (FACT) trial compared fulvestrant+anastrozole with anastrozole in 514 women of whom approximately two-thirds had received adjuvant tamoxifen. TTP and OS were identical in the two arms. The Southwest Oncology Group (SWOG) 0226 trial evaluated fulvestrant+anastrozole to anastrozole in 694 patients, of which ~40% had received adjuvant tamoxifen. In the anastrozole monotherapy arm, crossover to fulvestrant after progression was strongly encouraged. The median PFS was 15.0 months in the fulvestrant+anastrozole arm compared with 13.5 months in the anastrozole arm followed by fulvestrant arm (p=0.007). OS was 47.7 and 41.3 months, respectively (p=0.0049), despite the fact that 41% of patients crossed over to fulvestrant after progression.

**First-line or second-line therapy**

**Letrozole versus anastrozole**

A phase IIIb/IV trial compared letrozole with anastrozole in patients who had progressed on first-line aromatase inhibitors or who were clinically resistant to adjuvant tamoxifen. TTP, the primary end point, was 5.7 months in both arms. However, RR was significantly higher in the letrozole arm (19.1% vs 12.3%; p=0.013).

**Fulvestrant (250 mg) versus AIs**

Four studies comparing fulvestrant (250 mg) with aromatase inhibitors in the first-line or second-line setting were identified. All studies reported similar efficacy of the two drugs with regard to RR and TTP. No survival data were provided.

**Combination therapy versus single agent**

The Study of Faslodex versus Exemestane Clinical Trial (EFECT) trial compared fulvestrant (250 mg) with exemestane in patients who had progressed on an NSAI. In 60% of women, the agents were administered as third or higher lines of therapy. No significant difference in efficacy parameters was found.

**Studies of combinations of AI/fulvestrant and other drugs**

Table 3 shows efficacy results of AI/fulvestrant in combinations with other drugs. Nine trials were identified, including five randomised phase II and four phase III studies.

**COX-2 inhibitor**

One phase II and one phase III trial evaluated the addition of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to exemestane versus exemestane alone. In both studies, patients were AI naïve. None of the studies found significant differences in PFS. Thus, the addition of celecoxib did not add any clinically relevant benefit to exemestane.
<table>
<thead>
<tr>
<th>Reference</th>
<th>Treatment†</th>
<th>Number of patients</th>
<th>Patient population</th>
<th>Phase</th>
<th>Prior endocrine therapy</th>
<th>Prior chemotherapy for ABC</th>
<th>RR (%)(95% CI)</th>
<th>SD (%)(95% CI)</th>
<th>TTP/PFS (median; months) (95% CI)</th>
<th>OS (median; months) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First-line therapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iwata et al²⁴</td>
<td>Exemestane vs anastrozole</td>
<td>149</td>
<td>ER/PGR+ (HER2− 94/94%)</td>
<td>III</td>
<td>None: 83/83%; &gt;12 months adj TAM: 17/17%</td>
<td>None</td>
<td>43.8 (35.3 to 52.8)</td>
<td>31.1</td>
<td>13.8 (10.8 to 16.6)</td>
<td>11.1 (10.8 to 16.6)</td>
</tr>
<tr>
<td></td>
<td>Anastrozole</td>
<td>149</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liombart-Cussac et al²⁵</td>
<td>Exemestane</td>
<td>51</td>
<td>ER/PGR+ (UK 0/4%)</td>
<td>II, randomised</td>
<td>None: 49/50%; &gt;24 months adj TAMs: 51/50%</td>
<td>None</td>
<td>36.2 (18.5 to 45.9)</td>
<td>59.6 (CBR)</td>
<td>6.1 (2.4 to 9.6)</td>
<td>12.1 (7.3 to 16.8)</td>
</tr>
<tr>
<td></td>
<td>Anastrozole</td>
<td>52</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fulvestrant vs anastrozole</strong></td>
<td></td>
<td>102</td>
<td>ER/PGR+ (UK 1/3%)(HER2 2+/3+ 19/18%)</td>
<td>III (FIRST)</td>
<td>None: 72/78%; adj endocrine therapy: 28/22%</td>
<td>None</td>
<td>31.4</td>
<td>41.2</td>
<td>23.4</td>
<td>NR</td>
</tr>
<tr>
<td>Robertson et al²⁶</td>
<td>Fulvestrant 500 mg vs anastrozole</td>
<td>103</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31.1</td>
<td>35.0</td>
<td>13.1 (HR 0.66; p=0.01)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anastrozole</td>
<td>103</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31.1</td>
<td>35.0</td>
<td>13.1 (HR 0.66; p=0.01)</td>
<td></td>
</tr>
<tr>
<td><strong>Combination therapy vs single agent</strong></td>
<td></td>
<td>258</td>
<td>ER/PGR+</td>
<td>III (FACT)</td>
<td>None: 30/34%; adj TAM: 70/67%; adj AI: 2/1%</td>
<td>None</td>
<td>31.8</td>
<td>55.0 (CBR)</td>
<td>10.8</td>
<td>37.8</td>
</tr>
<tr>
<td>Bergh et al²⁸</td>
<td>Fulvestrant + anastrozole 250 mg</td>
<td>256</td>
<td>ER/PGR+</td>
<td>III (FACT)</td>
<td>None: 30/34%; adj TAM: 70/67%; adj AI: 2/1%</td>
<td>None</td>
<td>31.8</td>
<td>55.0 (CBR)</td>
<td>10.8</td>
<td>37.8</td>
</tr>
<tr>
<td></td>
<td>Anastrozole</td>
<td>256</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31.8</td>
<td>55.0 (CBR)</td>
<td>10.8</td>
<td>37.8</td>
</tr>
<tr>
<td>Mehta et al²⁹</td>
<td>Anastrozole + fulvestrant 250 mg</td>
<td>349</td>
<td>ER/PGR+ (HER2+ 10/9%)</td>
<td>III (SWOG 0226)</td>
<td>None: 60/60%; &gt;12 months adj TAM: 40/40%</td>
<td>None</td>
<td>22 (p=0.26)</td>
<td>70 (p=0.39)</td>
<td>13.5 (12.1 to 15.1) (HR 0.80; p=0.007)</td>
<td>41.3 (37.2 to 45.0) (HR 0.81; p=0.049)</td>
</tr>
<tr>
<td></td>
<td>Anastrozole</td>
<td>349</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>22 (p=0.26)</td>
<td>70 (p=0.39)</td>
<td>13.5 (12.1 to 15.1) (HR 0.80; p=0.007)</td>
<td>41.3 (37.2 to 45.0) (HR 0.81; p=0.049)</td>
</tr>
<tr>
<td><strong>First-line or second-line therapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>22 (p=0.26)</td>
<td>70 (p=0.39)</td>
<td>13.5 (12.1 to 15.1) (HR 0.80; p=0.007)</td>
<td>41.3 (37.2 to 45.0) (HR 0.81; p=0.049)</td>
</tr>
<tr>
<td>Rose et al³⁰</td>
<td>Letrozole vs anastrozole</td>
<td>356</td>
<td>ER/PGR+ (UK 21/8%)</td>
<td>IIb/IV</td>
<td>PD† on antioestrogen; adj antioestrogen: number NR</td>
<td>≤1</td>
<td>19.1 (15.7 to 22.9)</td>
<td>7.9</td>
<td>5.7 (5.1 to 6.0)</td>
<td>5.7 (4.6 to 6.1)</td>
</tr>
<tr>
<td></td>
<td>Anastrozole</td>
<td>357</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12.3 (9.6 to 15.6) (p=0.013)</td>
<td>10.6</td>
<td>5.7 (4.6 to 6.1) (p=0.92)</td>
<td></td>
</tr>
<tr>
<td><strong>Fulvestrant vs AIs</strong></td>
<td></td>
<td>222</td>
<td>ER/PGR+ or prior sensitivity to endocrine therapy (UK 23/16%)</td>
<td>III</td>
<td>PD on adj: 56/56%; PD on first-line endocrine therapy: 44/44% no prior AI</td>
<td>≤2</td>
<td>20.7</td>
<td>23.9</td>
<td>5.5</td>
<td>NR</td>
</tr>
<tr>
<td>Howell et al³¹</td>
<td>Fulvestrant 250 mg vs anastrozole</td>
<td>229</td>
<td>ER/PGR+ or prior sensitivity to endocrine therapy (UK 23/16%)</td>
<td>III</td>
<td>PD on adj: 56/56%; PD on first-line endocrine therapy: 44/44% no prior AI</td>
<td>≤2</td>
<td>20.7</td>
<td>23.9</td>
<td>5.5</td>
<td>NR</td>
</tr>
</tbody>
</table>

*Reference Treatment†: *ER/PGR+: Estrogen Receptor/Progesterone Receptor positive; *HER2−: HER2 negative; *TAM: Tamoxifen; *AI: Anti-estrogen; *RR: Response Rate; *SD: Standard Deviation; *TTP/PFS: Time To Progression/Progression Free Survival; *OS: Overall Survival; *NR: Not Reportable; *CI: Confidence Interval; *HR: Hazard Ratio; *p: Probability; †PD: Progression on Disease; ‡PD: Progression on Disease; §PD: Progression on Disease.
### Table 2 Continued

<table>
<thead>
<tr>
<th>Reference</th>
<th>Treatment*</th>
<th>Number of patients</th>
<th>Patient population</th>
<th>Phase</th>
<th>Prior endocrine therapy</th>
<th>Prior chemotherapy for ABC</th>
<th>RR (%) (95% CI)</th>
<th>SD (%) (95% CI)</th>
<th>TTP/PFS (median; months) (95% CI)</th>
<th>OS (median; months) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xu et al²</td>
<td>Fulvestrant 250 mg + placebo</td>
<td>121</td>
<td>ER+</td>
<td>III</td>
<td>PD after adj: NR; PD on first-line antioestrogen therapy: NR</td>
<td>≤2</td>
<td>10</td>
<td>48.2† (CBR)</td>
<td>3.6</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>Anastrozole + placebo</td>
<td>113</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.2 (HR 1.314; p=0.101)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>36.1 (OR 0.608; p=0.117)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Robertson et al³</td>
<td>Fulvestrant 250 mg + placebo</td>
<td>206</td>
<td>ER/PGR+ or prior sensitivity to endocrine therapy (UK 6/8% (ER/PGR− 5/5%))</td>
<td>III</td>
<td>PD on adj endocrine therapy: 56/50%; PD on first-line endocrine therapy: 57/56%; PD on adj endocrine therapy: 44/50%</td>
<td>No criteria</td>
<td>17.5</td>
<td>24.8</td>
<td>5.4</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>Anastrozole + placebo</td>
<td>194</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>18.6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.4 (HR 0.92; p=0.43)</td>
<td></td>
</tr>
<tr>
<td>Robertson et al³</td>
<td>Fulvestrant 250 mg + Anastrozole</td>
<td>428</td>
<td>ER/PGR+ or prior sensitivity to endocrine therapy (UK 15/12% (ER/PGR− 5/5%))</td>
<td>Combined data from two phase III (0020 and 0021)</td>
<td>PD on adj endocrine therapy: 57/56%; PD on first-line endocrine therapy: 43/44%</td>
<td>NR</td>
<td>19.2</td>
<td>24.3</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>16.5 (p=0.32)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24.3</td>
<td></td>
</tr>
<tr>
<td>Chia et al³⁴</td>
<td>Fulvestrant 250 mg</td>
<td>351</td>
<td>ER/PGR+</td>
<td>III (EFECT)</td>
<td>PD on NSAI‡; 60% ≥2 lines</td>
<td>≤1</td>
<td>7.4</td>
<td>32.2 (CBR)</td>
<td>3.7</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>Exemestane</td>
<td>342</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.7 (OR 1.12; p=0.736)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31.5 (OR 1.03; p=0.853)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.7 (HR 0.963; p=0.6531)</td>
<td></td>
</tr>
<tr>
<td>Combination therapy vs single agent</td>
<td>Johnston et al⁵</td>
<td>Fulvestrant +anastrozole</td>
<td>ER/PGR+</td>
<td>III (SoFEA)</td>
<td>PD on adj NSAI: 17/22/17%</td>
<td>≤1</td>
<td>8</td>
<td>33</td>
<td>20.2 (17.2 to 22.5)</td>
<td>19.4 (16.8 to 22.8)</td>
</tr>
<tr>
<td></td>
<td>Fulvestrant +placebo</td>
<td>231</td>
<td>HER2− (HER2+ 7/6/ 7%) (HER2 UK 43/33/ 36%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4.4 (3.4 to 5.4)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Exemestane</td>
<td>249</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>23 (NS)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.4 (3.0 to 4.6)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>23.9 (NS)</td>
<td></td>
</tr>
</tbody>
</table>

For RR, duration of TTP/PFS and OS, the number of decimals used by the authors is reported. ER/PGR+, HER2: % positive are given when possible.

* Doses of anastrozole, letrozole and exemestane were 1, 2.5 and 25 mg, respectively.
† Duration of SD not reported; if not marked, duration of SD reported ≥24 weeks or 6 months.
‡ Defined as relapse on adjuvant NSAI or within 6 months of stopping treatment or by progression on NSAI for advanced breast cancer.
ABC, advanced breast cancer; Adj, adjuvant; AI, aromatase inhibitor; CBR, clinical benefit rate; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; NR, not reported; NS, non-significant; NSAI, non-steroid aromatase inhibitor; PD, progressive disease; PFS, progression-free survival; PGR, progesterone receptor; RR, response rate; TAM, tamoxifen; TTP, time to progression; OS, overall survival; UK, unknown.
<table>
<thead>
<tr>
<th>Reference</th>
<th>Treatment*</th>
<th>Number of patient</th>
<th>Patient population Phase</th>
<th>Prior endocrine therapy</th>
<th>Prior chemotherapy for ABC</th>
<th>RR (%)</th>
<th>SD (%)</th>
<th>TTP/PFS (median; months) (95% CI)</th>
<th>OS (median; months) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COX-2 inhibitor</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dirix et al<strong>87</strong></td>
<td>Exemestane+celecoxib</td>
<td>56</td>
<td>ER/PGR+ or prior sensitivity to hormone receptor therapy (UK 30/38%)</td>
<td>PD on TAM; adj TAM: 62/50%; first-line TAM: 38/50%; no prior AI</td>
<td>≤1</td>
<td>21.5</td>
<td>21.4</td>
<td>5.2 (5.1 to 5.4)</td>
<td>16.4 (15.7 to 17.1)</td>
</tr>
<tr>
<td></td>
<td>Exemestane</td>
<td>55</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Falandry et al<strong>88</strong></td>
<td>Exemestane+celecoxib Exemestane + placebo</td>
<td>74</td>
<td>ER/PGR+ (UK 7/6%) (HER2+ 4/5%)</td>
<td>None: 43/39%; adj TAM: 57/61%; no prior AI</td>
<td>None</td>
<td>24</td>
<td>55†</td>
<td>9.8 (p=0.72)</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>83</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>mTOR inhibitor</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baselga et al<strong>89</strong>; Piccart et al<strong>90</strong></td>
<td>Exemestane+everolimus Exemestane + placebo</td>
<td>485</td>
<td>ER+HER2− III, BOLERO-2</td>
<td>Refractory NSAI; prior AI 100/100%; adj endocrine therapy: 28/28%; first-line endocrine therapy: 72/72%</td>
<td>≤1</td>
<td>7.0†</td>
<td>74.6§</td>
<td>10.6§ (p&lt;0.001)</td>
<td>31.0 (p=0.14)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>239</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HER1 inhibitor</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carlson et al<strong>91</strong></td>
<td>Anastrozole+gefitinib Fulvestrant 250 mg + gefitinib Fulvestrant</td>
<td>72</td>
<td>ER/PGR + II, randomised</td>
<td>None: 54/58%; adj endocrine therapy: 46/42%</td>
<td>≤2</td>
<td>25</td>
<td>19</td>
<td>5.3 (3.1 to 10.4)</td>
<td>30.3 (21.2 to 38.9+)</td>
</tr>
<tr>
<td></td>
<td>Letrozole/fulvestrant + bevacizumab</td>
<td>69</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Martin et al<strong>92</strong></td>
<td>Letrozole/fulvestrant</td>
<td>190</td>
<td>Hormone receptor+HER2− III</td>
<td>None:48/47%; None adj endocrine therapy: 52/53%</td>
<td>41</td>
<td>77 (CBR)</td>
<td>19.3 (16.5 to 22.1)</td>
<td>52.1 (14.4 to 71.5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fulvestrant</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Continued*
Table 3  Continued

<table>
<thead>
<tr>
<th>Reference</th>
<th>Treatment*</th>
<th>Number of patient</th>
<th>Patient population</th>
<th>Phase</th>
<th>Prior endocrine therapy</th>
<th>Prior chemotherapy for ABC</th>
<th>RR (%)</th>
<th>SD (%)</th>
<th>TTP/PFS (median; months) (95% CI)</th>
<th>OS (median; months) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>YARDLEY ET AL.</td>
<td>Exemestane + entinostat</td>
<td>64</td>
<td>ER+ II, randomised</td>
<td>PD on NSAI¶; adj endocrine therapy: 52/48%; first-line endocrine therapy: 84/86%</td>
<td>≤1</td>
<td>6.3</td>
<td>28.1† (CBR)</td>
<td>4.3 (3.3 to 5.4)</td>
<td>28.1 (21.2- not reached)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Exemestane + placebo</td>
<td>66</td>
<td>ER+ II, randomised</td>
<td>None: 59/55%; adj TAM: 29/30%; adj AI: 12/15%</td>
<td>None</td>
<td>43</td>
<td>38</td>
<td>10.2 (5.7 to 12.6)</td>
<td>Not powered for OS</td>
<td></td>
</tr>
<tr>
<td>FINN ET AL.</td>
<td>Letrozole + palbociclib</td>
<td>84</td>
<td>ER+ HER2− II, randomised</td>
<td>None: 84/80%; &gt;12 months adj AI: 16/20%</td>
<td>None</td>
<td>12.5</td>
<td>57.1†</td>
<td>(HR 0.925)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>IBRAHIM ET AL.</td>
<td>Letrozole + anti-MUC1 antibody (AS1402)</td>
<td>56</td>
<td>ER/PGR HER2− II, randomised</td>
<td>None: 84/80%; &gt;12 months adj AI: 16/20%</td>
<td>25.9</td>
<td>50.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For RR, duration of TTP/PFS and OS, the number of decimals used by the authors is reported.

ER/PGR+, HER2: % positive are given when possible.

*Doses of anastrozole, letrozole and exemestane were 1, 2.5 and 25 mg, respectively.

†Duration of SD not reported; if not marked, duration of SD reported ≥24 weeks or 6 months.

‡Defined as recurrence during or ≤12 months after adjuvant NSAI or PD during or within 1 month after treatment for advanced breast cancer.

§Central assessment.

¶Defined as relapse after adjuvant therapy administered for ≥12 months or PD on NSAI for MBC administered for ≥3 months.

ABC, advanced breast cancer; Adj, adjuvant; AI, aromatase inhibitor; CBR, clinical benefit rate; COX-2, cyclooxygenase-2; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; MBC, metastatic breast cancer; NR, not reported; NSAI, non-steroid aromatase inhibitor; PD, progressive disease; PFS, progression-free survival; PGR, progesterone receptor; RR, response rate; TAM, tamoxifen; TTP, time to progression, OS, overall survival; UK, unknown.
mTOR inhibitors
Among other mechanisms, endocrine resistance has been attributed to the crosstalk between ER signalling and the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway. Thus, dual targeting of both pathways may enhance efficacy of endocrine therapy.38

The Breast Cancer Trials of Oral EverOlimus-2 (BOLERO-2) study compared exemestane combined with the mTOR inhibitor everolimus with exemestane+placebo in patients previously treated with an NSAI. In total, 724 patients were randomised 2:1. No crossover was allowed. A significant difference in PFS was found favouring everolimus (10.6 vs 4.1 months).39 40 The trial was stopped early after a prespecified interim analysis found a significantly better PFS for the combination arm. However, OS was similar in the two arms.40

A retrospective, exploratory subgroup analysis in patients whose last treatment was in the (neo)adjuvant setting showed a median PFS in the combination arm of 15.2 vs 4.2 months in the exemestane+placebo arm; HR 0.32, 95% CI 0.18 to 0.57. Thus, the addition of everolimus nearly tripled PFS in the first-line setting.41 In contrast, the Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus as First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer (HORIZON) study comparing temsirolimus plus letrozole with letrozole failed to show any difference between treatment arms regarding PFS (9 months in both groups) and OS.42

HER1-targeted therapy
Preclinical studies have suggested that activation of the epidermal growth factor receptor (EGFR) pathway might be an important mechanism of endocrine resistance.43 Approximately 30% of HR-positive patients with breast cancer overexpress EGFR.44

In a randomised phase II trial, anastrozole+gefitinib was compared with fulvestrant (250 mg)+gefitinib. The RR, CBR and PFS did not differ for the two regimens. Median OS was 30.3 months for anastrozole+gefitinib vs 23.9 months for fulvestrant+gefitinib.45 Thus, efficacy rates were not clearly superior to endocrine therapy alone.46 Furthermore, the combinations had a less favourable safety profile compared with endocrine therapy.

Angiogenesis inhibitors
Preclinical studies have shown that vascular endothelial growth factor (VEGF) induced proliferation in breast cancer cell lines by interfering with the actions of oestrogens. Only one randomised study was identified. In total, 374 patients were randomised to first-line endocrine therapy (letrozole or fulvestrant)+bevacizumab. However, the addition of bevacizumab failed to produce a significant improvement in PFS or OS.47

Histone deacetylase inhibitor
A double-blind phase II trial of exemestane versus exemestane plus the histone deacetylase inhibitor entinostat showed no difference in the predefined end point PFS (4.3 vs 2.3 months; p=0.11). However, an exploratory analysis showed improved OS in the experimental arm (28.1 vs 19.8 months; p=0.036).48 In a subset of patients, an association of histone deacetylase inhibition with protein lysine acetylation and improved clinical outcome was demonstrated.

CDK4/6 inhibitor
The cyclin-dependent kinases (CDKs) are a large family of serine threonine kinases. Together with their regulatory partners, the cyclins, they play a crucial role in cell cycle control. Preclinical studies have shown synergistic effect of CDK inhibitors and tamoxifen as well as efficacy in a model of acquired tamoxifen resistance.49

Among several CDK4/6 inhibitors currently in development, palbociclib has been evaluated in a randomised phase II trial of letrozole+palbociclib. Median PFS was 10.2 months in the letrozole group compared with 20.2 months in the palbociclib+letrozole group (p=0.0004). The study was not powered to detect an OS benefit.50

Antibody directed against MUC1
MUC1 is an aberrantly glycosylated antigen, overexpressed in ~90% of breast cancers. Preclinical studies have shown a mechanistic interaction between MUC1 and ER, providing a rationale for evaluation of combination therapy.51 However, a randomised phase II study of letrozole+anti-MUC1 antibody ASI402 failed to demonstrate any benefit of adding ASI402 to letrozole.52

Studies of combinations of AI/fulvestrant and HER2-targeting agents
Results from three phase III trials evaluating endocrine therapy in combination with HER2-directed therapy are given in table 4.

Studies have shown significant inverse correlation between HER2 and ER expression. Furthermore, preclinical studies suggest an interaction between the two pathways.53 In the first-line setting, trastuzumab+anastrozole compared with anastrozole demonstrated significantly increased median PFS (4.8 vs 2.4 months) and increased RR (20.3% vs 6.8%).54

A phase III trial compared letrozole with letrozole plus the dual HER1/EGFR and HER2 tyrosine kinase inhibitor lapatinib in 1286 patients with HR-positive metastatic breast cancer as first-line therapy. In 219 HER2-positive patients, the addition of lapatinib reduced the risk of disease progression (p=0.019) and increased median PFS (8.2 vs 3.0 months).55 Finally, a phase III trial including 295 patients with advanced breast cancer previously treated with an AI compared fulvestrant (250 mg) plus lapatinib with fulvestrant plus placebo. In the total patient population, no differences
Table 4  Summary of phase II and III trials of HER2-directed therapy in combination with endocrine therapy in patients with HER2-positive hormone receptor-positive metastatic breast cancer

<table>
<thead>
<tr>
<th>Reference</th>
<th>Treatment*</th>
<th>Number of patients</th>
<th>Patient population</th>
<th>Phase</th>
<th>Prior endocrine therapy</th>
<th>Prior chemotherapy for ABC</th>
<th>RR (%) (95% CI)</th>
<th>SD (%) (95% CI)</th>
<th>TTP/PFS (median; months) (95% CI)</th>
<th>OS (median; months) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NSAI; trastuzumab</strong>&lt;br&gt;Kaufman et al&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Anastrozole + trastuzumab&lt;br&gt;Anastrozole</td>
<td>103&lt;br&gt;104</td>
<td>ER/PGR+ HER2+&lt;br&gt;ER/PGR+ HER2+</td>
<td>III&lt;br&gt;III</td>
<td>None: 37/29%; adj TAM: 60/66%; first-line endocrine therapy: 3/5%; no prior HER2-directed therapy</td>
<td>None</td>
<td>20.3&lt;br&gt;6.8 (p=0.018)</td>
<td>42.7 (33.0 to 52.9)&lt;br&gt;27.9 (19.5 to 37.5) (CBR)</td>
<td>4.8&lt;br&gt;2.4 (HR 0.63; p=0.0016)</td>
<td>28.5&lt;br&gt;23.9 (p=0.325)</td>
</tr>
<tr>
<td><strong>NSAI; lapatinib</strong>&lt;br&gt;Johnston et al&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Letrozole + lapatinib&lt;br&gt;Letrozole + placebo</td>
<td>642 (111 HER2+)&lt;br&gt;644 (108 HER2+</td>
<td>ER/PGR+ HER2+&lt;br&gt;ER/PGR+ HER2+</td>
<td>III&lt;br&gt;III</td>
<td>None: 51/43%; adj endocrine therapy: 49–57%; prior AI ≤ 1%; prior HER2-directed therapy ≤ 1%</td>
<td>None</td>
<td>28 (HER2+)&lt;br&gt;15 (OR 0.4; 0.2 to 0.9; p=0.021)</td>
<td>48 (HER2+, CBR)&lt;br&gt;29 (OR 0.2 to 0.8; p=0.003)</td>
<td>8.2 (HER2+)&lt;br&gt;3.0 (HR 0.71; p=0.019)</td>
<td>32.3&lt;br&gt;33.3 (HR 0.74; p=0.113)</td>
</tr>
<tr>
<td><strong>Fulvestrant; lapatinib</strong>&lt;br&gt;Burstein et al&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Fulvestrant 500 mg + lapatinib&lt;br&gt;Fulvestrant 500 mg + placebo</td>
<td>146 (24 HER2+&lt;br&gt;145 (30 HER2+</td>
<td>ER/PGR+ HER2+&lt;br&gt;ER/PGR+ HER2+</td>
<td>III&lt;br&gt;III</td>
<td>Prior TAM: 57/57%; prior AI: 97/97%; setting NR; prior trastuzumab: 2/3%</td>
<td>≤ 1</td>
<td>38 (14 to 70) (HER2+)&lt;br&gt;16 (5 to 45)&lt;br&gt;38&lt;br&gt;16</td>
<td>4.7 (HER2+)&lt;br&gt;3.8 (HR 1.04; p=0.37)</td>
<td>30.0&lt;br&gt;26.4 (HR 0.91; p=0.25)</td>
<td></td>
</tr>
</tbody>
</table>

For RR, duration of TTP/PFS and OS, the number of decimals used by the authors is reported.
ER/PGR+, HER2: % positive are given when possible.

*Doses of anastrozole and letrozole were 1 and 2.5 mg, respectively.

ABC, advanced breast cancer; adj, adjuvant; AI, aromatase inhibitor; CBR, clinical benefit rate; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; NR, not reported; NSAI, non-steroid aromatase inhibitor; PFS, progression-free survival; PRG, progesterone receptor; RR, response rate; SAI, steroid aromatase inhibitor; TAM, tamoxifen; TTP, time to progression; OS, overall survival.
in PFS or OS were found. In 54 HER2-positive patients, however, the addition of lapatinib resulted in a longer median PFS (5.9 vs 3.3 months).56

DISCUSSION

Guidelines unanimously recommend endocrine therapy as first choice in patients with HR-positive, HER2-negative disease independent of metastatic site, unless rapid response is needed or in case of doubts regarding the endocrine responsiveness of the tumour.57 58 This strategy is partly based on consensus between specialists3 and partly on a Cochrane review published in 2005 and updated in 2010.59 No studies published after 2000 have addressed this question.

Treatment selection

First-line therapy

In general, trials evaluating the different AIs and/or fulvestrant were conducted before the time of systematic HER2 analyses; thus, patients with unknown HR status were included in some of the trials. In addition, studies were conducted at a time when the use of adjuvant AI was uncommon.

In the first-line setting, NSAIs were more effective than tamoxifen regarding TTP,7 8 10 13 whereas the difference between exemestane and tamoxifen was limited and depended on the statistical test used.15 16 Except for the P025 trial in which a significant OS benefit was found for letrozole compared with tamoxifen,60 no OS benefit was demonstrated in the trials.

A recent meta-analysis of six trials including 2560 patients6 7 10 15 16 61 comparing an AI with tamoxifen found a significant difference favouring AI regarding RR and CBR. However, a trend towards improved survival was non-significant.62 In contrast, two meta-analyses showed a significant OS benefit of AIs compared with other endocrine therapies.63 64 Thus, if not used in the adjuvant setting or if discontinued >12 months, an NSAI is given upfront. In general, studies reporting on this phenomenon included few patients,25 74–76 but findings across different studies seem to consent that no cross-resistance exists. This is supported by one randomised trial,34 in which exemestane was compared with fulvestrant after failure of an NSAI; no significant differences in efficacy parameters were reported. For the reverse sequence, that is NSAI after failure of an SAI, only one study was identified in which a 55% RR of an NSAI after prior exposure to exemestane was reported.74

Differences in binding ability, including different binding sites at the aromatase enzyme, kinetics (reversibility) and androgen-agonistic effects, might potentially explain the findings. However, the pharmacologic and molecular mechanisms behind the phenomenon remain unclear.

A limited number of small phase II studies and retrospective studies have demonstrated activity of AIs and fulvestrant in the third-line setting.77–79 Importantly, the response to previous therapy had little impact on efficacy of the drugs. The results might be due to selection bias and small number of patients. Anyhow, results suggested that the drugs might be active in latter lines of therapy.

In the SWOG 0226 trial, the combination of anastrozole and fulvestrant (250 mg) increased PFS compared with anastrozole alone (15 vs 13.5 months). The combination therapy also increased the median OS by ~6 months despite the fact that 41% of patients crossed over to fulvestrant after progression.29 The FACT trial, which also compared anastrozole±fulvestrant (250 mg) as first-line therapy, found no difference in outcome.28 A
possible explanation for the discordant results could be that a higher percentage of patients had received prior hormonal therapy in the FACT trial (66–70% in FACT vs 40% in SWOG). Thus, a subanalysis of the SWOG trial did not show a significant improvement in PFS in patients who had received adjuvant tamoxifen. In addition, the FACT trial was slightly smaller and included patients with local recurrence only, as well as patients who had recurrence while on adjuvant endocrine therapy.

No guidelines consider combination hormonal therapy to be a standard first-line treatment option. However, in postmenopausal patients who have not received prior hormonal therapy, this option deserves further investigation.

Generally, guidelines do not definitively recommend specific endocrine treatment cascades, particularly regarding the best treatment option following progression on first-line therapy.57 67

Endocrine therapy combined with other agents

Studies on endocrine therapy in combination with inhibitors of angiogenesis, COX-2 inhibitors and HER1 inhibitors did not show any benefit of the combinations.

The histone deacetylase inhibitor entinostat in combination with exemestane is currently evaluated in a phase III study (NCT02115282). Results are expected in July 2017.

The addition of everolimus to exemestane in the pivotal BOLERO-2 study undoubtedly resulted in a clinically meaningful extension of median PFS by ~4.5 months after recurrence or progression on an NSAI. An exploratory analysis of first-line therapy showed a nearly tripled PFS. However, data on OS failed to show any significant difference between the two regimens, although an absolute difference of almost 4.5 months was observed. In total, 55% of patients experienced grade 3 or 4 side effects in the everolimus arm, and 29% discontinued everolimus because of lack of tolerability. Overall, the number of serious adverse events (SAEs) did not differ from numbers seen in trials including chemotherapy challenging the strategy of applying the most tolerable regimen first.80 Thus, the safety profile may limit practical use and compliance. The randomised phase II study BOLERO-6 comparing everolimus plus exemestane with everolimus alone with capcitabine (NCT01783444) might provide some answers.

A similar effect of addition of everolimus was found in a randomised phase II study of tamoxifen+everolimus including 111 HER2-negative, HR-positive postmenopausal women with metastatic breast cancer and prior exposure to an AI. The benefit of everolimus was mainly seen in women with acquired resistance to an AI.81

In contrast, the phase III HORIZON study evaluating the addition of temsirolimus to letrozole failed to show any benefit of the combination.42 The discordant results are not well understood. A possible explanation could be the intermittent doses used in the HORIZON study. Also, a high rate of toxic effects in this study leading to dose reductions/cessation of temsirolimus could affect the outcome. However, the key difference between the two studies was differences in the study populations. In the HORIZON study, 58% were AI naïve and it was unlikely that acquired resistance was evident in many of the patients. Thus, it has been hypothesised that mTOR inhibitors are more effective in patients previously exposed to endocrine therapy.

A recent meta-analysis compared everolimus plus exemestane with fulvestrant 250 and 500 mg, respectively. The combination of everolimus and exemestane appeared more efficacious than fulvestrant with regard to PFS. A subgroup analysis of patients who had received prior AI showed similar results.82

Yet, there are no predictive biomarkers to identify patients who benefit from addition of an mTOR inhibitor.

Recent treatment guidelines from a range of countries recommend addition of everolimus to exemestane for patients recurring/progressing during or following an NSAI even in the presence of visceral disease.57 58 83 84

Currently, three specific CDK4/6 inhibitors palbociclib, abemaciclib and ribociclib are being tested in clinical trials. More recently, the randomised phase II PALbociclib: Ongoing trials in the Management of breast cancer (PALOMA)-1 trial showed an almost double PFS after addition of palbociclib to letrozole.50 On 3 February 2015, the US FDA granted accelerated approval to palbociclib for use in combination with letrozole.85 To confirm the impressive results, the phase III study (PALOMA-2) is ongoing and results are expected in October 2016 (NCT01740427). Recently, the phase III PALOMA-3 trial including 521 premenopausal and postmenopausal patients with advanced breast cancer who were randomised to fulvestrant+palbociclib or placebo+goserelin demonstrated a significant increase in PFS (9.2 vs 3.8 months, HR 0.42, 95% CI 0.32 to 0.56; p<0.001). The number of deaths at the time of the analysis was insufficient to assess OS.86

Several phase III studies are in progress with all three CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer. The observed toxicities so far are predominantly hematological, characterised by limited neutropenia. Other common adverse events were infections, fatigue and gastrointestinal toxicity. The toxicities seem manageable. Currently, data are too limited to differentiate between the compounds. No predictive biomarkers to identify patients who benefit from addition of a CDK4/6 inhibitor are available.87

Studies of combinations of AI/fulvestrant and HER2-targeting agents

Approximately half of the patients with HER2-positive breast cancer are also HR positive. Concomitant treatment with anastrozole and therapy directed against HER2 provided a significantly better outcome. The
endocrine resistance. 

Drug resistance to single-agent molecular mechanisms has been identified, and these findings have been demonstrated in preclinical studies. 

Nonetheless, combination chemotherapy with HER2-directed therapy as first-line treatment is generally preferred.

Future perspectives

A major limitation of endocrine therapy is intrinsic and acquired resistance. Although expression of ER is strongly predictive of response to endocrine therapies, approximately one-third of ER-positive cancers do not respond or relapse after an initial response. In the past decade, there have been major efforts to understand the molecular mechanism responsible for development of endocrine resistance. 

Drug resistance to single-agent therapy might be driven by pathway reactivation, suggesting that one limitation lies in the inability to fully block the pathway. mTOR and CDK4/6 inhibition might represent ways to overcome this. Furthermore, future strategies currently under evaluation include combining endocrine therapy with inhibitors of growth factor receptors or downstream signalling pathways. For a comprehensive review, see Palmieri et al. On the other hand, ER-positive breast cancer is biologically heterogeneous, and many patients have long-lasting benefit of endocrine monotherapy. Yet, prognostic biomarkers to identify patients who will do well with endocrine therapy alone as well as biomarkers to predict benefit from combination therapy are lacking.

CONCLUSION

Conventional treatment with an AI or fulvestrant may be an adequate treatment option for the majority of patients. mTOR and CDK4/6 inhibition might represent substantial advances for patients with HR-positive, HER2-negative advanced breast cancer. However, there is an urgent need for prospective biomarker-driven trials to identify patients for whom the treatments are cost-effective.

Competing interests

None declared.

Provenance and peer review

Not commissioned; externally peer reviewed.

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant

Iben Kümler, Ann S Knoop, Christina A R Jessing, Bent Ejlertsen and Dorte L Nielsen

ESMO Open 2016 1:
doi: 10.1136/esmoopen-2016-000062

Updated information and services can be found at:
http://esmoopen.bmj.com/content/1/4/e000062

These include:

References
This article cites 90 articles, 35 of which you can access for free at:
http://esmoopen.bmj.com/content/1/4/e000062#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Open access (101)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/